LYEL (Lyell Immunopharma) Short Interest

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LYEL Lyell Immunopharma Inc LYEL
55 GF Score
Price $13.19
GF Value $5.26
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Lyell Immunopharma Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

LYEL vs ALXO, ARMP, NAGE: Short Interest Comparison

For the Biotechnology subindustry, Lyell Immunopharma's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lyell Immunopharma Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lyell Immunopharma's Short Interest distribution charts can be found below:

* The bar in red indicates where Lyell Immunopharma's Short Interest falls into.


LYEL
55GF Score
Lyell Immunopharma Inc LYEL
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Lyell Immunopharma (LYEL) Overvalued in 2026?

Based on GuruFocus' analysis, Lyell Immunopharma stock appears to be overvalued. The current stock price of $13.19 is trading 150.8% above its estimated GF Value™ of $5.26. GuruFocus considers Lyell Immunopharma to be Significantly Overvalued.

Key valuation signals for LYEL:

  • Short Interest:
  • GF Value™: $5.26 vs. price of $13.19 (150.8% above fair value)
  • GF Score™: 55/100 with 6 warning signs

No single metric tells the full story. See the LYEL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lyell Immunopharma Business Description

Address 201 Haskins Way, South San Francisco, CA, USA, 94080
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.
55GF Score

Get the complete analysis for LYEL

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.19
Price
$5.26
GF Value